|
|
|
|
LEADER |
03401nma a2200937 u 4500 |
001 |
EB002195116 |
003 |
EBX01000000000000001332581 |
005 |
00000000000000.0 |
007 |
cr||||||||||||||||||||| |
008 |
240202 ||| eng |
020 |
|
|
|a 9783036594170
|
020 |
|
|
|a 9783036594163
|
020 |
|
|
|a books978-3-0365-9416-3
|
100 |
1 |
|
|a Mascellino, Maria
|
245 |
0 |
0 |
|a Molecular Research in Human Microbiome
|h Elektronische Ressource
|
260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
300 |
|
|
|a 1 electronic resource (210 p.)
|
653 |
|
|
|a virulence
|
653 |
|
|
|a human gut
|
653 |
|
|
|a aging
|
653 |
|
|
|a dysbiosis
|
653 |
|
|
|a bacteria
|
653 |
|
|
|a right-sided colon cancer
|
653 |
|
|
|a inflammation
|
653 |
|
|
|a Huntington's disease
|
653 |
|
|
|a n/a
|
653 |
|
|
|a scientific technology
|
653 |
|
|
|a molecular genetic diagnostics
|
653 |
|
|
|a Humanities / bicssc
|
653 |
|
|
|a Social interaction / bicssc
|
653 |
|
|
|a metagenomics
|
653 |
|
|
|a gut-brain axis
|
653 |
|
|
|a gut microbiota
|
653 |
|
|
|a sex differences
|
653 |
|
|
|a geographical distribution of H. pylori antibiotic resistance
|
653 |
|
|
|a Clostridium difficile infection
|
653 |
|
|
|a immune protection
|
653 |
|
|
|a Helicobacter pylori
|
653 |
|
|
|a platelets
|
653 |
|
|
|a tumor microbiome
|
653 |
|
|
|a pregnancy
|
653 |
|
|
|a neurodegeneration
|
653 |
|
|
|a proteome
|
653 |
|
|
|a SARS-CoV-2
|
653 |
|
|
|a antibiotic consumption
|
653 |
|
|
|a gut microbiome
|
653 |
|
|
|a 16S rRNA sequencing
|
653 |
|
|
|a liver cancer
|
653 |
|
|
|a immune
|
653 |
|
|
|a methods for determining H. pylori resistance
|
653 |
|
|
|a intestinal microbiota
|
653 |
|
|
|a nasopharyngeal microbiome
|
653 |
|
|
|a metabolites
|
653 |
|
|
|a placenta
|
653 |
|
|
|a colon cancer
|
653 |
|
|
|a antibiotic resistance
|
653 |
|
|
|a FGR
|
653 |
|
|
|a cancer treatment
|
653 |
|
|
|a age differences
|
653 |
|
|
|a neuropathy
|
653 |
|
|
|a cardiotoxicity
|
653 |
|
|
|a left-sided colon cancer
|
653 |
|
|
|a pain
|
653 |
|
|
|a human microbiome
|
653 |
|
|
|a phenotypic methods for determining antibiotic resistance
|
653 |
|
|
|a mast cells
|
653 |
|
|
|a gastrointestinal microbiome
|
653 |
|
|
|a IBS
|
653 |
|
|
|a metabolomics
|
653 |
|
|
|a microbiome
|
700 |
1 |
|
|a Mascellino, Maria
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
028 |
5 |
0 |
|a 10.3390/books978-3-0365-9416-3
|
856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/8272
|7 0
|x Verlag
|3 Volltext
|
856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/128805
|z DOAB: description of the publication
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 140
|
082 |
0 |
|
|a 600
|
520 |
|
|
|a This reprint turns out to be very important for the pathologies deriving from the gut microbiome and its disorders. Human health seems to be correlated with the status of our microbiome, which plays a vital role in our health. The human microbiome is associated with a wide range of diseases, from non-neoplastic to tumorigenesis, including cancer, inflammation, intestinal damage, etc. Following these statements, it is possible to deduce the paramount importance of the role of the gut microbiome and the relative consequences for human well-being.
|